Evaluation of the FYNA Research OPM MEG Device for Locating Epileptic Foci as Part of Pre-surgical Assessment of Epilepsy

NCT07281222 · tracked via the Priya Life Science France tracker

Sponsor

Hospices Civils de Lyon

Phase

Not applicable

Started

2026-09

Last updated

2026-04-23

Condition(s) studied

Epilepsy

Investigational drug(s) / intervention(s)

MEG OPMMEG SQUID

MEG OPM: The OPM MEG sensor (FYNA Research device) is a new sensor technology for MEG (magnetoencephalography). It consists of 48 detectors (helium-4 magnetometers) that are positioned on the patient's head using a support system that can be adjusted to fit the size of their head. The patient goes to the MEG center at CERMEP (patients included in Lyon) or INS (patients included in Marseille), changes clothes, and removes any makeup. Metal-free clothing designed for MEG is provided. The tracking coils are put in place. The patient is then placed in the MEG, and their positioning and comfort are checked again. The OPM MEG acquisition takes about 60 minutes.

MEG SQUID: The MEG SQUID is the classical MEG (magnetoencephalography). It consists of a set of sensors placed in a rigid helmet, in contact with the head. The patient goes to the MEG center at CERMEP (patients included in Lyon) or INS (patients included in Marseille), changes clothes, and removes any makeup. Metal-free clothing designed for MEG is provided. The tracking coils are put in place. The patient is then placed in the MEG, and their positioning and comfort are checked again. The OPM MEG acquisition takes about 60 minutes.

Study summary

The success of epilepsy surgery depends largely on the reliability of the preoperative localization of the epileptogenic zone. The conventional method for determining the area to be removed is based on a complex assessment involving an electroencephalogram (EEG) coupled with simultaneous video recording of seizures (video SEEG), a brain MRI, and a fluorodeoxyglucose positron emission tomography scan (PET-FDG).

At present, epilepsy surgery cannot cure all patients. Since the prognosis for surgery depends primarily on the ability to delineate the epileptogenic zone, it is essential to develop new diagnostic approaches that can accurately detect epileptic foci.

MEG (magnetoencephalography) is a non-invasive brain mapping technique based on the magnetic fields created by neuronal activity. Numerous studies have shown that it is a highly effective technique for locating epileptic foci, and more accurate than EEG. However, MEG remains relatively uncommon (three centers in France) because current conventional systems (MEG SQUID) are difficult to use, expensive, require significant structural constraints for installation, and are not very sensitive (sensors are distant from the scalp).

Mag4Health has developed a new MEG device, the "MEG FYNA Research", which records brain magnetic activity using 48 or 96 sensors (4He optical pumping magnetometers, or "OPMs"). Compared to conventional MEG (SQUID MEG), this OPM MEG technology is more compact, less expensive, more sensitive, and allows the sensors to be placed directly on the scalp.

The EPI-OPM study is a prospective, uncontrolled, bicenter clinical investigation that aims to evaluate the diagnostic performance of this device.

The main objective is to assess the value of the OPM MEG device for localizing the epileptogenic zone compared to the reference method in epileptic patients undergoing epilepsy surgery.

Patients (children and adults) will be enrolled at the Lyon University Hospital and the Marseille University Hospital.

Each patient will undergo an OPM MEG examination and a SQUID MEG examination (SQUID MEG only for patients in Lyon), in addition to the clinical procedures performed as part of routine care: intracranial EEG recording (SEEG) and MRI if necessary, followed by surgery to resect the epileptic focus.

The performance of the OPM MEG device in locating epileptic foci will be validated by surgical results and invasive EEG recordings. The localization of epileptic foci using the OPM MEG system will be compared with that obtained using the SQUID MEG system (conventional MEG) and other pre-surgical assessment tests carried out as part of routine care. Finally, we will describe tolerance to the recordings and assess overall comfort and feasibility using appropriate questionnaires.

Eligibility

Sex

ALL

Min age

6 Years

Max age

65 Years

Healthy volunteers

Inclusion Criteria: 1. Patients aged 6 to 65 2. Patients suffering from partial epilepsy that has been developing for at least 2 years, drug-resistant, regardless of the presumed topographical origin or suggested cause (lesional with or without MRI abnormality) and for whom the following have been decided and planned: either i) a surgical procedure to resect the epileptogenic zone without prior intracranial EEG recording or ii) intracranial EEG recording necessary before a possible cortical resection procedure 3. Patients who have undergone routine prolonged scalp video EEG recording showing interictal paroxysmal abnormalities 4. Patients motivated to participate effectively in the project 5. Patients who have signed an informed consent form to participate in the study Exclusion Criteria: 1. Patients with neurological or psychiatric disorders or a history of neurological or psychiatric disorders, sleep disorders other than epilepsy that may impact the variability or quality of the data or the cooperation and retention of the participant, which will be assessed by the principal investigator or co-investigator during the inclusion interview. 2. Patients with contraindications common to MEG and MRI examinations: * Metal in the body that is incompatible with the examination (pacemaker, implanted pump including insulin pump, neurostimulator, cochlear implants or other hearing devices, metal prosthesis, intracerebral/surgical clips for aneurysms, implantable defibrillators, ferromagnetic foreign bodies in the eyes or brain in the upper body, ventriculoperitoneal neurosurgical shunt valves, dental braces or steel pivots for dental root canals, ferromagnetic foreign bodies in the upper body) * Claustrophobia 3. Pregnant women, breastfeeding women, or women who have given birth within the last 6 months. 4. Patients under guardianship, curatorship, or judicial protection 5. Patients deprived of their liberty 6. Patients not affiliated with a social security system or beneficiaries of such a system

Primary outcome measure(s)

Percentage of cases in which the location of epileptic foci identified by MEG OPM confirmed the location identified by pre-surgical assessment (EEG, SEEG, MRI, PET-FDG) when surgery was successful, one year after its completion (composite outcome) — 1 year after surgery (18 months after inclusion)
To do this, the existence of a spatial overlap between the location of the epileptic focus in MEG and the area operated on in patients will be assessed. The location of the area operated on in cured patients is considered to be the reference location of the epileptogenic zone. For each patient included, the location of the preoperative MEG epileptic focus will be determined by source modeling applied to the detected epileptic spikes. The area operated on will be determined on the postoperative MRI, and the success of the operation will be determined by the Engel score, which summarizes the postoperative evolution of epilepsy in terms of seizure frequency in the context of routine care.

Trial sites (3)

Facility	City	Region
Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Service Explorations Fonctionnelles Pédiatriques	Bron	France
Hôpital Neurologique, Hospices Civils de Lyon, Service Explorations Fonctionnelles Neurologiques et Epileptologie	Bron	France
Hôpital de la Timone, AP-HM Service d'Epileptologie et Rythmologie Cérébrale	Marseille	France

More Hospices Civils de Lyon trials in France

Phenotyping Acute Non-Severe Anemia in the Emergency Department Starting soon

HCC Innervation Assessment Active, not recruiting

Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD Recruiting

A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE Recruiting

Intestinal Hyperechogenicity Confirmed by Evaluation of Gray Spectra Starting soon

Other trials for the same condition

Glioma Intraoperative MicroElectroCorticoGraphy Starting soon

RESting-state Functional MRI for Prediction of Post-surgical Prognosis In Pediatric Drug-Resistant Epilepsy Recruiting

Optimization of the Parameters of Vagal Nerve Stimulation Active, not recruiting

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures Recruiting

Risk Prevention Program and Therapeutic Patient Education Program of Patients With Uncontrolled Epilepsy Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07281222 on ClinicalTrials.gov ↗ ← All trials in France